Clinical Trial Update: Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating donafenib in combination with capecitabine as postoperative adjuvant therapy for biliary tract cancer with high recurrence risk; curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Donafenib (donafenib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Biliary Malignant Tumors | Phase 2 | Status: RECRUITING